Barclays’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-53
| Closed | – | – | 7674 |
|
|
2018
Q4 | $0 | Hold |
53
| – | – | ﹤0.01% | 7816 |
|
|
2018
Q3 | $0 | Hold |
53
| – | – | ﹤0.01% | 7719 |
|
|
2018
Q2 | $0 | Sell |
53
-6,149
| -99% | -$9.42K | ﹤0.01% | 7652 |
|
|
2018
Q1 | $8K | Buy |
6,202
+1,456
| +31% | +$3.04K | ﹤0.01% | 6720 |
|
|
2017
Q4 | $11K | Buy |
4,746
+4,069
| +601% | +$10.3K | ﹤0.01% | 6505 |
|
|
2017
Q3 | $2K | Buy |
677
+605
| +840% | +$2.04K | ﹤0.01% | 6729 |
|
|
2017
Q2 | $0 | Sell |
72
-116
| -62% | -$382 | ﹤0.01% | 7287 |
|
|
2017
Q1 | $0 | Buy |
188
+135
| +255% | +$525 | ﹤0.01% | 7274 |
|
|
2016
Q4 | $0 | Sell |
53
-282
| -84% | -$1.16K | ﹤0.01% | 7128 |
|
|
2016
Q3 | $1K | Buy |
335
+282
| +532% | +$912 | ﹤0.01% | 6564 |
|
|
2016
Q2 | $0 | Hold |
53
| – | – | ﹤0.01% | 7008 |
|
|
2016
Q1 | $0 | Sell |
53
-878
| -94% | -$3.4K | ﹤0.01% | 6877 |
|
|
2015
Q4 | $3K | Buy |
931
+145
| +18% | +$668 | ﹤0.01% | 5724 |
|
|
2015
Q3 | $2K | Sell |
786
-332
| -30% | -$1.52K | ﹤0.01% | 6475 |
|
|
2015
Q2 | $4K | Buy |
1,118
+300
| +37% | +$2.88K | ﹤0.01% | 6643 |
|
|
2015
Q1 | $5K | Sell |
818
-332
| -29% | -$1.64K | ﹤0.01% | 6661 |
|
|
2014
Q4 | $3K | Buy |
+1,150
| New | +$4.63K | ﹤0.01% | 7106 |
|
Barclays's AST Position: Q1 2019 in Review
Barclays sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 53 shares.
Barclays first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $11K in Q4 2017. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Barclays reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Barclays sold 53 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
- Barclays first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- Barclays's Asterias Biotherapeutics Inc. Series A position peaked at $11K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Barclays's 13F filing for Q1 2019, filed 15 May 2019.